微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 59.83% | -3.33% | -7.27% | 53/159 | 22.98% | 艾力斯 | 96.74% | 行业排名> |
| 2024-06-30 | 64.52% | -4.3% | -14.85% | 43/159 | 33.39% | 首药控股 | 98.96% | 行业排名> |
| 2024-03-31 | 75.77% | 5.96% | 3.73% | 25/159 | 51.73% | 迪哲医药 | 97.73% | 行业排名> |
| 2023-12-31 | 73.05% | 12.1% | 18.05% | 31/159 | 51.53% | 百利天恒 | 97.99% | 行业排名> |
| 2023-09-30 | 61.89% | -19.25% | -8.2% | 49/159 | 32.76% | 百利天恒 | 98.92% | 行业排名> |
| 2023-06-30 | 67.42% | -10.7% | -5.73% | 40/159 | 38.65% | 迈威生物 | 98.93% | 行业排名> |
| 2023-03-31 | 71.51% | -10.05% | 9.74% | 34/159 | 52.91% | 迈威生物 | 99.59% | 行业排名> |
| 2022-12-31 | 65.17% | -8.95% | -14.97% | 48/159 | 53.74% | 迈威生物 | 99.8% | 行业排名> |
| 2022-09-30 | 76.64% | -0.99% | 1.51% | 31/159 | 6.69% | 迈威生物 | 99.46% | 行业排名> |
| 2022-06-30 | 75.5% | -2.84% | -5.04% | 31/159 | 21.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-03-31 | 79.5% | -2.19% | 11.07% | 24/159 | 54.47% | 迈威生物 | 99.67% | 行业排名> |
| 2021-12-31 | 71.58% | -4.25% | -7.53% | 40/159 | 55.21% | 迈威生物 | 99.44% | 行业排名> |
| 2021-09-30 | 77.4% | -4.83% | -0.38% | 24/159 | 47.01% | 迈威生物 | 98.57% | 行业排名> |
| 2021-06-30 | 77.7% | -5.1% | -4.41% | 25/159 | 47.45% | 首药控股 | 99.93% | 行业排名> |
| 2021-03-31 | 81.28% | -4.61% | 8.73% | 16/159 | 54.21% | 艾力斯 | 99.41% | 行业排名> |
| 2020-12-31 | 74.76% | -8.39% | -8.08% | 31/159 | -144.37% | 艾力斯 | 98.7% | 行业排名> |
| 2020-09-30 | 81.33% | -1.64% | -0.67% | 20/159 | 56.57% | 艾力斯 | 99.4% | 行业排名> |
| 2020-06-30 | 81.88% | -2.94% | -3.91% | 14/159 | 54.32% | 首药控股 | 99.94% | 行业排名> |
| 2020-03-31 | 85.21% | -0.22% | 4.42% | 11/159 | 55.5% | 泽璟制药 | 99.96% | 行业排名> |
| 2019-12-31 | 81.61% | -2.57% | -1.31% | 15/159 | -1213.38% | 微芯生物 | 95.14% | 行业排名> |
| 2019-09-30 | 82.68% | 0.41% | -1.98% | 10/159 | 55.47% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-06-30 | 84.35% | 0.49% | -1.23% | 12/159 | 55.47% | 微芯生物 | 95.81% | 行业排名> |
| 2019-03-31 | 85.4% | 3.6% | 1.97% | 9/159 | 51.37% | 微芯生物 | 96.09% | 行业排名> |
| 2018-12-31 | 83.76% | 0.94% | 1.71% | 17/159 | -205.91% | 微芯生物 | 96.11% | 行业排名> |
| 2018-09-30 | 82.35% | 2.31% | -1.9% | 13/159 | 54.25% | 微芯生物 | 95.5% | 行业排名> |
| 2018-06-30 | 83.94% | 9.32% | 1.83% | 12/159 | 53.68% | 微芯生物 | 96.27% | 行业排名> |
| 2018-03-31 | 82.44% | 7.9% | -0.65% | 12/159 | 54.19% | 贝达药业 | 95.47% | 行业排名> |
| 2017-12-31 | 82.97% | 8.11% | 3.09% | 13/159 | 52.58% | 贝达药业 | 95.51% | 行业排名> |
| 2017-09-30 | 80.49% | 2% | 4.82% | 8/159 | 49.32% | 贝达药业 | 95.54% | 行业排名> |
| 2017-06-30 | 76.78% | 3.87% | 0.5% | 9/159 | 48.02% | 贝达药业 | 95.74% | 行业排名> |
| 2017-03-31 | 76.4% | 2% | -0.45% | 10/159 | 46.89% | 退市金泰 | 96.19% | 行业排名> |
| 2016-12-31 | 76.75% | 2.97% | 3.82% | 13/159 | 48.44% | 贝达药业 | 95.81% | 行业排名> |
| 2016-06-30 | 73.92% | -1.16% | -0.82% | 10/159 | 46.2% | 退市金泰 | 95.93% | 行业排名> |
| 2015-12-31 | 74.54% | 2.02% | -0.34% | 9/159 | 46.24% | 贝达药业 | 95.58% | 行业排名> |
| 2015-06-30 | 74.79% | 2% | 2.37% | 8/159 | 45.36% | 贝达药业 | 95.89% | 行业排名> |